ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

crinecerfont

Also written as “Crinecerfont”, “NBI-74788” and “SSR125543”.

Its studies are mostly in Adrenal Hyperplasia, Congenital · Depressive Disorder, Major, led by 2 companies.

Drug pageCrinecerfont: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 24, 20207 company-led studies, 4 open or runningNext primary completion: Mar 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciencesits history only64 open or runningphase 3since Jul 24, 2020May 2, 2018Mar 2028phase 2 · NCT07536269
Sanofi10 open or runningphase 2since Dec 17, 2009Dec 17, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2009First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT01034995 · 580 enrolled · Belgium, Canada, Chile and more
  2. Dec 9, 2018Named crinecerfontINNProposed as its International Nonproprietary Name in WHO's List 120 · before, NBI-74788, SSR125543

TargetBeta

CRHR1 →read by rule
“Corticotropin releasing factor receptor 1 antagonist”ChEMBL 37, by rule

Studies

The one study Sanofi leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01034995Depressive Disorder, Major · Belgium, Canada, Chile and more2CompletedMar 2011580

How it is read

Names in the registry

  • “Crinecerfont”, 5 entries
  • “NBI-74788”, 1 entry
  • “SSR125543”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.